June 25, 2013

The Food and Drug Administration has given special designation to a drug made by Raptor Pharmaceuticals for a rare metabolic disease.

June 25, 2013

The healthcare industry continues to prepare for ACA implementation and the expected influx of newly eligible patients, said Emdeon's Kevin Mahoney. Many pharmacies are changing their staffing models in preparation for customers with expanded Medicaid benefits — especially as we approach the New Year. This is a good time for me to remind you to be thinking about your eligibility program.

June 25, 2013

Drug makers may be allowed to seek approval for a generic version of an eye drug made by Allergan based on lab tests rather than clinical trials, according to published reports.

June 24, 2013

A White House trade policy leader has been appointed as U.S. Trade Representative.

June 24, 2013

Generic drug makers cannot be held liable if patients suffer harmful side effects after taking their drugs, the Supreme Court has ruled in a 5-4 decision.

June 20, 2013

Pharmaceutical wholesaler H.D. Smith will buy a majority interest in a Cincinnati-based patient assistance, pharmaceutical brand support and reimbursement company.

June 20, 2013

Tris Pharma has hired a former buyer from AmerisourceBergen to head its generic drug business, the company said.

June 19, 2013

More responsible use of drugs could save the U.S. healthcare system more than $200 billion per year, according to a new study by the research arm of IMS Health.

June 18, 2013

Teva Pharmaceutical Industries will spend up to $165 million to buy a company developing a drug to prevent viral respiratory infections.

June 18, 2013

Half a loaf, the saying goes, is better than none. For the generic drug industry, that means that the Supreme Court handed it a partial victory Monday by ruling that “pay for delay” patent settlements between brand name and generic drug companies aren’t necessarily illegal and should be considered on a case-by-case, “rule of reason” approach by the Federal Trade Commission, which staunchly opposes the practice.

June 17, 2013

One of the greatest challenges facing the pharmaceutical industry today is medication nonadherence — a fact that has not gone unnoticed by McKesson.

A variety of pharmacy-based solutions, designed to help pharmacy owners drive better results both from a patient outcomes and a profitability standpoint by offering services that promote long-term adherence and opportunities for patients to enroll in clinical trials, will be on display for ideaShare attendees through McKesson’s Clinical Services network.

June 17, 2013

Drug maker Johnson & Johnson plans to spend up to $1 billion to acquire a privately owned company developing a drug for prostate cancer.

June 17, 2013

Patent settlements between brand and generic drug makers commonly referred to as "pay-for-delay" settlements are not necessarily against the law, the Supreme Court ruled Monday.

June 13, 2013

Drug maker Actavis is working with nonprofit pharmaceutical company Medicines360 to make low-cost intrauterine devices available to women, the two said.

June 13, 2013

The Food and Drug Administration has approved a drug made by Amgen for treating a rare and usually noncancerous bone tumor, the agency said Thursday.

June 12, 2013

More than 200 drugs are under development for cardiovascular disease, according to a drug industry trade group.

June 12, 2013

Pfizer will receive more than $2 billion from Teva Pharmaceutical Industries and Sun Pharmaceutical Industries to settle a case concerning a gastroesophageal reflux disease drug.

June 10, 2013

Anglo-Swedish drug maker AstraZeneca will pay up to $1.15 billion for a U.S. developer of drugs for respiratory diseases, AstraZeneca said Monday.

June 10, 2013

A 26-member joint panel comprising the Food and Drug Administration's Endocrinologic and Metabolic Drugs and Drug Safety and Risk Management advisory committees voted to support modifying or removing the risk evaluation and mitigation strategy protocol for GlaxoSmithKline's Type 2 diabetes drug Avandia (rosiglitazone).

Historically, the FDA has followed advisory committee votes when making a decision on the marketing of a drug even though it is not bound by them, but assuming the agency follows the panel's advice, it could mean a lot for the controversial drug and the way it's dispensed. But even if Avandia winds up on retail pharmacy shelves again, it faces a very different landscape from its heyday.

June 7, 2013

Actavis is hoping to become the first to market generic versions of a contraceptive and a sedative, the drug maker said.

June 7, 2013

A joint Food and Drug Administration expert panel voted to recommend keeping a controversial GlaxoSmithKline diabetes drug available for certain patients, GSK said.

June 5, 2013

South Korean drug maker Hanmi Pharmaceutical Co. and U.S. partner Amneal Pharmaceuticals have made an agreement in federal court concerning a generic heartburn drug.

June 4, 2013

The Center for Healthcare Supply Chain Research, HDMA’s nonprofit research foundation, and Genentech on Tuesday honored Robert Belknap, executive director of trade sales and operations for Boehringer Ingelheim Pharmaceuticals, with the 2013 Nexus Award for Lifetime Achievement.

June 4, 2013

The House of Representatives voted Monday to pass a bill that would establish national standards for the pharmaceutical supply chain.